Icahn homes in on Biogen Idec again
This article was originally published in Scrip
Executive Summary
Carl Icahn is planning another boardroom brawl for Biogen Idecas the company's fourth-quarter earnings edged up by almost 3% to $206.7 million. The activist shareholder has nominated four candidates to join the biotech's board, a sign that he will pursue the company for the second time in two years.